D-0001-2018 Class III Terminated
FDA drug recall D-0001-2018 was initiated by Pfizer Inc. on Jul 12, 2017 and is designated Class III. Reason for recall: CGMP Deviations: Firm failed to control impurity for color change at the API stage. The recall status is terminated (terminated Jul 16, 2020). Affected quantity: 32,276 10 mL vials.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 11, 2017
- Initiation Date
- Jul 12, 2017
- Termination Date
- Jul 16, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 32,276 10 mL vials
Product description
Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.
Reason for recall
CGMP Deviations: Firm failed to control impurity for color change at the API stage.
Distribution pattern
Nationwide
Code information
Lot: 51275DD; Exp. 09/01/17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0001-2018
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026